Developing a new eye drop to lower eye pressure for glaucoma patients
Official title: Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation
Funded at Tavo Biotherapeutics, INC · NIH-10922072 · Data updated 2026-11-12
This study is working on a new type of eye drop that lasts longer and helps lower eye pressure for people with glaucoma, making it easier for them to stick to their treatment and experience fewer side effects.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tavo Biotherapeutics, INC NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,066,178 |
| NIH project number | 1R44EY036343-01 |
| Project ID | NIH-10922072 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glaucoma who struggle with current treatment regimens due to side effects or adherence issues.
✕Less likely to help
Patients who do not have glaucoma or those who are not able to use eye drops may not benefit from this research.
What this research studies
This research focuses on creating a first-in-class extended release formulation of eye drops designed to lower intraocular pressure (IOP) in patients with glaucoma. The approach aims to improve patient adherence by reducing the frequency of eye drop administration and minimizing side effects associated with current treatments. By engineering a more effective delivery system, the research seeks to provide a sustained IOP-lowering effect, addressing the critical need for better management of this condition. The study will involve pre-clinical development and adherence to Good Manufacturing Practices (GMP) to ensure safety and efficacy.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and convenient treatment option for glaucoma patients, potentially reducing the risk of blindness.
How similar studies have gone: Previous research has shown promise in developing extended release formulations for other conditions, suggesting potential success for this novel approach in glaucoma treatment.
Where this research is happening
-
Tavo Biotherapeutics, INC
Memphis, United States Active
Researchers
- Principal investigator: Johnson, Dianna Ammons — Tavo Biotherapeutics, INC
- Study coordinator: Johnson, Dianna Ammons
Related research
Other NIH-funded projects on the same topics.
-
Long‑lasting eye medicine to lower eye pressure for glaucoma
A long‑acting eye treatment is being made to lower eye pressure for adults with glaucoma who have trouble using daily eye drops.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.